Advertisement

What Causes Tardive Dyskinesia?

Learn how neuroleptic medications can cause this involuntary movement disorder.

Medically reviewed in January 2021

Tardive dyskinesia, sometimes shortened as TD, is a disorder that occurs as a result of taking antipsychotic medications. It is also sometimes caused by medications used to treat neurological and GI disorders.

When a person has TD, they experience involuntary muscle movements. These movements are described as repetitive and jerky, and they can affect both the face and the rest of the body—for example, repetitive blinking of the eyelids, fish-like movements of the mouth, or moving the fingers as if typing. Tardive translates to “delayed” and dyskinesia translates to “abnormal movement.”

Neuroleptic medications
TD is a side effect of drugs called neuroleptic medications. Also called antipsychotic medications, neuroleptic medications are used to treat a variety of psychiatric disorders, most commonly schizophrenia, but also other conditions, including depression, manic episodes, and neurological disorders like Parkinson’s disease.

First- and second-generation
While the exact cause of schizophrenia is unknown, the disorder is associated with abnormalities in neurotransmitters. Neurotransmitters are chemical messengers that help brain cells interact with other brain cells. Some examples include dopamine, serotonin, and epinephrine (also known as adrenaline). Neurotransmitter abnormalities are also associated with depression, bipolar disorder, and Parkinson’s disease.

Neuroleptic drugs work by altering the function of neurotransmitters. There are two broad categories:

  • First-generation neuroleptic medications, which act on dopamine receptors.
  • Second-generation neuroleptic medications, which act on dopamine receptors as well as serotonin receptors. While second-generation neuroleptics act on dopamine receptors, they have a difference mechanism of action than the first-generation drugs.

As you can probably guess from the category names, first-generation neuroleptic medications are older and second-generation neuroleptics are newer. First-generation neuroleptics were introduced in the 1950s and are still in use today. Second-generation refers to neuropeptic drugs that became available starting in the 1980s. By the early 2000s, the vast majority of neuroleptic drugs that were prescribed were second-generation. Generally, second-generation neuroleptics are associated with fewer side effects.

Treatment
Because people with TD often depend on the medication that is causing TD, the disorder can be difficult to treat. Treatment may involve discontinuing the current medication and switching to another—which must be done with caution and always under the guidance of a qualified healthcare provider. Symptoms of TD can become worse when a medication is discontinued, and symptoms may persist when a person switches to a different neuroleptic medication.

There are two drugs that are approved by the FDA for the treatment of TD. Both drugs are vesicular monoamine transporter 2 (VMAT2) inhibitors, which work by regulating chemical signaling in the brain, which helps reduce the nerve signaling that causes involuntary movement. VMAT2 inhibitors are also used to treat other involuntary movement disorders.

Sources:
National Organization for Rare Disorders. "Tardive Dyskinesia."
MedicineNet. "Medical Definition of Tardive Dyskinesia."
Elsevier Patient Education. "Tardive Dyskinesia."
MedlinePlus. "Tardive Dyskinesia."
University of Arkansas for Medical Sciences. "Glossary of Movement Terms."
Muhammad Atif Ameer and Abdolreza Saadabadi. "Neuroleptic Medications." StatPearls, 2020.
J.P. Kesby, D.W. Eyles, J.J. McGrath and J.G. Scott. "Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience." Translational Psychiatry, 2018. Vol. 8, No. 30.
Ralf Brisch, Arthur Saniotis, et al. "The Role of Dopamine in Schizophrenia from a Neurobiological and Evolutionary Perspective: Old Fashioned, but Still in Vogue." Frontiers in Psychiatry, 2014. Vol. 5, No. 47.
J.R. Cooper. "Neurotransmitters." International Encyclopedia of the Social & Behavioral Sciences, 2001.
David R. DeMaso and Heather J. Walter. "Psychopharmacology." Nelson Textbook of Pediatrics, 2020.
Sarayu Vasan and Ranjit K. Padhy. "Tardive Dyskinesia." StatPearls, 2020.
Herbert Y. Meltzer. "What's atypical about atypical antipsychotic drugs?" Current Opinions in Pharmacology, 2004. Vol. 4, No. 1.
National Organization for Rare Disorders. "Tardive Dyskinesia."
Drugs.com. "VMAT2 inhibitors."

Featured Content

article

Managing TD While Managing a Mental Health Disorder

How tardive dyskinesia can impact how you mange schizophrenia and what you can do about it.
article

5 Answers About Tardive Dyskinesia

What patients and caregivers should know about causes, prevalence, and treatment options for TD.
article

Describing the Emotional Impact of TD

Learn how the impact of this involuntary movement disorder extends beyond physical symptoms.
video

What Does It Mean To Be a Self-Advocate with TD?

Being a self-advocate with tardive dyskinesia means communicating what you need and what you desire for treatment.
article

Tardive Dyskinesia: A Glossary of Terms

Key terms to help patients and caregivers better understand TD.